These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis. Hochberg MC Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069 [TBL] [Abstract][Full Text] [Related]
10. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. White WB; West CR; Borer JS; Gorelick PB; Lavange L; Pan SX; Weiner E; Verburg KM Am J Cardiol; 2007 Jan; 99(1):91-8. PubMed ID: 17196469 [TBL] [Abstract][Full Text] [Related]
11. Factors associated with celecoxib and rofecoxib utilization. Rawson NS; Nourjah P; Grosser SC; Graham DJ Ann Pharmacother; 2005 Apr; 39(4):597-602. PubMed ID: 15755796 [TBL] [Abstract][Full Text] [Related]
12. Cardiovascular issues of COX-2 inhibitors and NSAIDs. Wong M; Chowienczyk P; Kirkham B Aust Fam Physician; 2005 Nov; 34(11):945-8. PubMed ID: 16299629 [TBL] [Abstract][Full Text] [Related]
13. Cardiovascular effects of selective cyclooxygenase-2 inhibitors. Krum H; Liew D; Aw J; Haas S Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):265-70. PubMed ID: 15151474 [TBL] [Abstract][Full Text] [Related]
14. Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man. Dajani EZ; Islam K J Physiol Pharmacol; 2008 Aug; 59 Suppl 2():117-33. PubMed ID: 18812633 [TBL] [Abstract][Full Text] [Related]
15. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Johnsen SP; Larsson H; Tarone RE; McLaughlin JK; Nørgård B; Friis S; Sørensen HT Arch Intern Med; 2005 May; 165(9):978-84. PubMed ID: 15883235 [TBL] [Abstract][Full Text] [Related]
16. Cyclooxygenase-2 inhibitors: what went wrong? James MJ; Cleland LG Curr Opin Clin Nutr Metab Care; 2006 Mar; 9(2):89-94. PubMed ID: 16477171 [TBL] [Abstract][Full Text] [Related]
17. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults. Huang WF; Hsiao FY; Wen YW; Tsai YW Clin Ther; 2006 Nov; 28(11):1827-36. PubMed ID: 17213003 [TBL] [Abstract][Full Text] [Related]
18. Celecoxib and cardiovascular risks. Brophy JM Expert Opin Drug Saf; 2005 Nov; 4(6):1005-15. PubMed ID: 16255660 [TBL] [Abstract][Full Text] [Related]
19. Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study. Rahme E; Bardou M; Dasgupta K; Toubouti Y; Ghosn J; Barkun AN Rheumatology (Oxford); 2007 Feb; 46(2):265-72. PubMed ID: 16844699 [TBL] [Abstract][Full Text] [Related]
20. Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis. Chan CC; Reid CM; Aw TJ; Liew D; Haas SJ; Krum H J Hypertens; 2009 Dec; 27(12):2332-41. PubMed ID: 19887957 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]